David Robbins

Title: Innovations by David Robbins in Colorectal Cancer Diagnosis

Introduction

David Robbins is an accomplished inventor based in Stevenson Ranch, CA (US). He has made significant contributions to the field of genetics, particularly in the diagnosis of colorectal cancer. His work focuses on the mutations in human MLH1 and MSH2 genes, which are crucial for understanding hereditary non-polyposis colorectal cancer (HNPCC).

Latest Patents

David Robbins holds a patent for "Mutations in human MLH1 and human MSH2 genes useful in diagnosing colorectal cancer." This patent includes variant human MLH1 and MSH2 genes that are instrumental in diagnosing HNPCC. The methods outlined in his patent provide ways to determine a patient's susceptibility to developing HNPCC. Additionally, the patent describes methods and compositions for identifying new variant MLH1 or MSH2 genes. Experimental models for HNPCC that incorporate these variant genes are also included in his patent.

Career Highlights

David Robbins is associated with Diadexus, Inc., where he continues to advance research in genetic diagnostics. His work has the potential to significantly impact the early detection and treatment of colorectal cancer, thereby improving patient outcomes.

Collaborations

David has collaborated with notable colleagues, including Juili Lillian Lin-Goerke and Jessica C Ling. These collaborations have further enriched his research and contributed to the development of innovative diagnostic methods.

Conclusion

David Robbins is a key figure in the field of genetic research, particularly in the diagnosis of colorectal cancer. His innovative work on MLH1 and MSH2 genes has the potential to transform how hereditary non-polyposis colorectal cancer is diagnosed and managed.